Pharmesis International Ltd. Returns to Profitability with New Herbal Segment

Pharmesis International Ltd. ( (SG:BFK) ) has issued an update.

Pharmesis International Ltd. reported a return to profitability in FY2024 with a net profit of RMB8.3 million, driven by a 48.2% increase in revenue to RMB67.6 million. This growth was largely attributed to the new TCH procurement segment, which contributed significantly in its first half-year. The company leverages its experience and established network to maintain a competitive edge in sourcing herbs directly from local farmers in Sichuan. The entry into this segment did not materially change the group’s risk profile, as it aligns with their existing expertise. Additionally, Mr. Chew Heng Ching was redesignated as non-Independent non-executive chairman, stepping down from his roles as chairman of key committees but remaining a member.

More about Pharmesis International Ltd.

Pharmesis International Ltd. operates in the pharmaceutical industry, focusing on the procurement and distribution of Traditional Chinese Herbs (TCH). The company sources herbal medicines from Sichuan, China, and processes and distributes them through its established industry network.

Average Trading Volume: 8,738

Technical Sentiment Signal: Sell

Current Market Cap: S$18.39M

For a thorough assessment of BFK stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue